Overall and allele-specific expression of the SMC1A gene in female Cornelia de Lange syndrome patients and healthy controls
EPIGENETICS
Authors: Parenti, Ilaria; Rovina, Davide; Masciadri, Maura; Cereda, Anna; Azzollini, Jacopo; Picinelli, Chiara; Limongelli, Giuseppe; Finelli, Palma; Selicorni, Angelo; Russo, Silvia; Gervasini, Cristina; Larizza, Lidia
Abstract
Cornelia de Lange syndrome (CdLS) is a rare multisystem disorder characterized by facial dysmorphisms, limb anomalies, and growth and cognitive deficits. Mutations in genes encoding subunits (SMC1A, SMC3, RAD21) or regulators (NIPBL, HDAC8) of the cohesin complex account for approximately 65% of clinically diagnosed CdLS cases. The SMC1A gene (Xp11.22), responsible for 5% of CdLS cases, partially escapes X chromosome inactivation in humans and the allele on the inactive X chromosome is variably expressed. In this study, we evaluated overall and allele-specific SMC1A expression. Real-time PCR analysis conducted on 17 controls showed that SMC1A expression in females is 50% higher than in males. Immunoblotting experiments confirmed a 44% higher protein level in healthy females than in males, and showed no significant differences in SMC1A protein levels between controls and patients. Pyrosequencing was used to assess the reciprocal level of allelic expression in six female carriers of different SMC1A mutations and 15 controls who were heterozygous at a polymorphic transcribed SMC1A locus. The two alleles were expressed at a 1:1 ratio in the control group and at a 2:1 ratio in favor of the wild type allele in the test group. Since a dominant negative effect is considered the pathogenic mechanism in SMC1A-defective female patients, the level of allelic preferential expression might be one of the factors contributing to the wide phenotypic variability observed in these patients. An extension of this study to a larger cohort containing mild to borderline cases could enhance our understanding of the clinical spectrum of SMC1A-linked CdLS.
The landscape of somatic mutations in epigenetic regulators across 1,000 paediatric cancer genomes
NATURE COMMUNICATIONS
Authors: Huether, Robert; Dong, Li; Chen, Xiang; Wu, Gang; Parker, Matthew; Wei, Lei; Ma, Jing; Edmonson, Michael N.; Hedlund, Erin K.; Rusch, Michael C.; Shurtleff, Sheila A.; Mulder, Heather L.; Boggs, Kristy; Vadordaria, Bhavin; Cheng, Jinjun; Yergeau, Donald; Song, Guangchun; Becksfort, Jared; Lemmon, Gordon; Weber, Catherine; Cai, Zhongling; Dang, Jinjun; Walsh, Michael; Gedman, Amanda L.; Faber, Zachary; Easton, John; Gruber, Tanja; Kriwacki, Richard W.; Partridge, Janet F.; Ding, Li; Wilson, Richard K.; Mardis, Elaine R.; Mullighan, Charles G.; Gilbertson, Richard J.; Baker, Suzanne J.; Zambetti, Gerard; Ellison, David W.; Zhang, Jinghui; Downing, James R.
Abstract
Studies of paediatric cancers have shown a high frequency of mutation across epigenetic regulators. Here we sequence 633 genes, encoding the majority of known epigenetic regulatory proteins, in over 1,000 paediatric tumours to define the landscape of somatic mutations in epigenetic regulators in paediatric cancer. Our results demonstrate a marked variation in the frequency of gene mutations across 21 different paediatric cancer subtypes, with the highest frequency of mutations detected in high-grade gliomas, T-lineage acute lymphoblastic leukaemia and medulloblastoma, and a paucity of mutations in low-grade glioma and retinoblastoma. The most frequently mutated genes are H3F3A, PHF6, ATRX, KDM6A, SMARCA4, ASXL2, CREBBP, EZH2, MLL2, USP7, ASXL1, NSD2, SETD2, SMC1A and ZMYM3. We identify novel loss-of-function mutations in the ubiquitin-specific processing protease 7 (USP7) in paediatric leukaemia, which result in decreased deubiquitination activity. Collectively, our results help to define the landscape of mutations in epigenetic regulatory genes in paediatric cancer and yield a valuable new database for investigating the role of epigenetic dysregulations in cancer.